Global Life Sciences Royalty Rates and Deal Terms Survey, Implications and Applications
Wednesday, March 29, 2017
1:00-2:30 p.m. (Eastern)
12:00-1:30 p.m. (Central)
11:00-12:30 p.m. (Mountain)
10:00-11:30 a.m. (Pacific)
LES members: Free
Join us as our expert panel discusses methods and applications for use of the RR and Deal Term Survey data. We will discuss how our panel members and their teams use the survey, suggest further applications, and acknowledge some limitations of the data.
About the RRDT survey:
The Life Sciences Sectors of LES USA & Canada and LES International have partnered to conduct a landmark GLOBAL survey of royalty rates and deal terms for recent deals conducted in the past two years. The results represent significant information on early stage deals from universities, private biotech companies and deals submitted by international companies outside the USA and Canada.
This landmark global survey is unique for the biopharmaceutical industry. The results presented in this session will be highlights of the Survey Report to be published in February 2017. The findings provide insights certain to raise questions or challenge conventional thinking, especially for contemporary deals in recent and turbulent years.
- Value of aggregated data
- Using the RR and DT Survey for term sheet comparisons
- Academic vs. Corporate use/participation in RR and DT survey
- Prevalence of valuation methodology
Leslie Molony, Sr. Director Business Development, Sanford Burnham Prebys Medical Discovery Institute
Ben Bonifant, Partner, Triangle Insights Group, LLC
Jennifer Dyer, Executive Director, USC Stevens Center for Innovation
Sean Sheridan, Principal, Charles River Associates
Elizabeth Gildea, Licensing Director, GE Healthcare
Jim McCarthy, Corporate and Business Development, Corp Dev Ventures
Arthur D. Misyan, Executive Director, BD&L, Merck & Co., Inc.
For information about the upcoming Webinar Wednesday event, please follow this link:
LES Webinar Wednesday Information